Biotechnology

Beyond Biotech podcast 49 – precision medicine

[ad_1]

This week, we had a discussion about precision medicine with Tero Silvola, CEO at BC Platforms. We also discussed the 4Pharma acquisition.

This acquisition expands BCP’s global service offering to accelerate the translation of innovations into clinical practice. In addition, 4Pharma customers will benefit from additional services in the RWD area through the BC Platform technology.

4Pharma (HQ Turku, Finland and Lund, Sweden) was founded over 20 years ago, and has collaborations with around 70 clients in the Nordics, Central Europe and the US The company has developed expertise in a wide range of therapeutic areas including oncology, neurology, ophthalmology, musculoskeletal , respiratory diseases, infectious diseases, and gynecology.

The company provides medical research services in several areas: high-quality, cost-effective solutions for the management and delivery of clinical trial data, including real-world data; medical writing; collection, analysis and reporting of patient safety data including data visualization; trial design & interpretation; health technology assessment; global regulatory filings with FDA (USA), EMA (Europe) and PMDA (Japan); and risk-based patient monitoring. With this acquisition, BCP strengthens its capabilities in this area for drug development and clinical research, further diversifying its portfolio of services for pharmaceutical and biotechnology clients.

Tero Silvola, CEO at BC Platforms, said: “This exciting acquisition of the extraordinary 4Pharma delivers impressive healthcare data intelligence expertise. This is in line with our vision to build a world-leading analytics platform to enable the pharmaceutical industry advances in precision medicine, improve drug development efficiency and patient outcomes. This broadens our service offerings to healthcare and lifesciences customers, as well as connects data partners in an interoperable global federated network. We combine omics and clinical data assets around the world, without compromising data privacy and security. This allows our customers to conduct new research and find exciting new insights to advance healthcare that is important to help patients receive better care and treatment.”

Tero Oinonen, CEO of 4Pharma, said: “4Pharma’s business has grown rapidly over two decades through the provision of advanced biostatistics, data management and medical writing services by highly experienced pharmaceutical industry professionals. Our clinical trial data management and statistical expertise has been at the heart of several successful global regulatory filings with world-leading regulators in the US, Europe and Japan, and we have conducted hundreds of clinical studies for our global clients.

“Our team has a wealth of high-quality industry expertise that takes our clients beyond their data. We are very happy to join BCP. There are clear synergies and shared values ​​between our companies, including the possibility to incorporate new technologies, 4Pharma’s BCP data network and biostatistics and data management services. We share a data-driven mindset and open dedication to science, which can propel the provision of healthcare data management and analytics to new heights.”

[ad_2]

Source link

Related Articles

Back to top button